Cargando…
PD-L1(+) neutrophils as novel biomarkers for stage IV melanoma patients treated with nivolumab
Melanoma displays a rising incidence, and the mortality associated with metastatic form remains high. Monoclonal antibodies that block programmed death (PD-1) and PD Ligand 1 (PD-L1) network have revolutionized the history of metastatic disease. PD-L1 is expressed on several immune cells and can be...
Autores principales: | Cristinziano, Leonardo, Modestino, Luca, Capone, Mariaelena, Madonna, Gabriele, Mallardo, Domenico, Giannarelli, Diana, D’Angelo, Grazia, Ferrara, Anne Lise, Loffredo, Stefania, Varricchi, Gilda, Vanella, Vito, Festino, Lucia, Ascierto, Paolo Antonio, Galdiero, Maria Rosaria |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9398490/ https://www.ncbi.nlm.nih.gov/pubmed/36016960 http://dx.doi.org/10.3389/fimmu.2022.962669 |
Ejemplares similares
-
Baseline neutrophil-to-lymphocyte ratio (NLR) and derived NLR could predict overall survival in patients with advanced melanoma treated with nivolumab
por: Capone, Mariaelena, et al.
Publicado: (2018) -
Melanoma-derived soluble mediators modulate neutrophil biological properties and the release of neutrophil extracellular traps
por: Modestino, Luca, et al.
Publicado: (2023) -
VEGF-A in Cardiomyocytes and Heart Diseases
por: Braile, Mariantonia, et al.
Publicado: (2020) -
Neutrophil Extracellular Traps, Angiogenesis and Cancer
por: Poto, Remo, et al.
Publicado: (2022) -
Soluble CD73 as biomarker in patients with metastatic melanoma patients treated with nivolumab
por: Morello, Silvana, et al.
Publicado: (2017)